R ectal cancer is a common disease, with an estimated 40,000 new diagnoses in the united states this year. 1 Radical resection (RR), including low anterior and abdominoperineal resection, remains the gold standard for treatment. these procedures carry the risk for significant long-and short-term morbidity, including urinary and sexual dysfunction, low anterior syndrome, and the need for a permanent colostomy. [2] [3] [4] [5] [6] [7] local excision (le) is an attractive option because it avoids these mor-
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bidities. Both transanal excision and transanal endoscopic microsurgery (tem) have demonstrated minor morbidity rates of 0% to 28%. 8, 9 although there was a significant increase in the rate of le for rectal cancer between 1990 and 2003, since 2000, there have been numerous studies published showing inferior overall and disease-free survival compared with RR. 8, [10] [11] [12] [13] [14] [15] the rate of local recurrence after le ranges from 7% to 21% for t1 lesions and from 26% to 47% for t2 lesions. [16] [17] [18] furthermore, initial reports demonstrated that, if disease recurs after le, salvage therapy does not provide the same long-term survival as RR. 19 Current guidelines state that le is an appropriate treatment option for patient with t1 tumors without lymphovascular invasion. Patients with t2 lesions are recommended to undergo RR, but LE may be considered if used in conjunction with chemoradiation therapy. 20 Recently published population-based studies have reported le rates for early stage rectal cancer as high as 28.0% overall, with 46.5% for t1 and 16.8% for t2 disease. 21, 22 since 2001, data revealing high rates of local recurrence have led to close scrutiny of the role of le. 10, 13, 15, [23] [24] [25] [26] [27] [28] Discussion has largely been confined to specialty societies, and it is unclear what the impact is in the general surgery community. this study used the survey of epidemiology and end Results (seeR)-medicare database to examine the change in use of le for rectal cancer from 2000 to 2009. We also identified patient, surgeon, and hospital factors associated with le in an attempt to understand the impact of controversies around the use of le in the treatment of early stage rectal cancer.
PATIENTS AND METHODS
We obtained data from the seeR-medicare files for patients diagnosed with rectal adenocarcinoma between 2000 and 2009. 29 We excluded patients from the study who were enrolled in health maintenance organizations during the 6 months before and 3 months after diagnosis. We then excluded patients <66 and >99 years old. Patients <65 years old in the medicare data consist of patients who are disabled or have end-stage renal disease. Because of their unusual characteristics, we did not include them in our analysis. to ensure a year-long look-back period for the purposes of determining comorbidity, we also excluded 65-year-old patients, because they would not have 1 year of previous medicare records.
We identified those patients who underwent either RR or le of their rectal tumor based on International Classification of Diseases, ninth Revision, and Current Procedural terminology 2006 codes. We included patients if they had an operative code within 9 months of the date of their cancer diagnosis. if patients had both an le code and an RR code, they were included in the RR group. next, we excluded patients who had received neoadjuvant radiation and/or chemotherapy, because pretreatment clinical stage could not be determined. this ensured that the patients in our study had pathologically confirmed, early stage disease, unaffected by preoperative downstaging. from this cohort, we included patients with a diagnosis of rectal carcinoma in situ (tis) and stage i (t1/2, n0) rectal cancer. finally, we used the seeR Patient entitlement and Diagnosis summary file, in combination with identification of Current Procedural terminology/International Classification of Diseases, ninth Revision, codes in the medicare files, to identify the use of adjuvant radiation and chemotherapy.
our primary outcome was report of le or RR and changes in the rate of le over time. Before analysis, we defined the variables that we believed would be associated with le. these are classified as patient (age, race, sex, comorbidity, socioeconomic status, year of diagnosis, and tumor t stage), surgeon (year of medical school graduation and surgical specialty), and hospital (national Cancer institute [nCi] designation and teaching status) characteristics.
Patient age was analyzed as a categorical variable (66-70, 71-75, 76-80, 81-85, and ≥86 years). Because of the small number of nonwhite patients, we collapsed race into 3 categories-white, black, and other. Patient comorbidity was assessed using the Romano modification of the Charlson comorbidity index. 30 Because of the small number of patients with scores >2, we collapsed the RomanoCharlson values into 3 categories, 0 (low), 1 (moderate), and ≥2 (high). the percentage of people living below the poverty line in a patient census tract was used as a proxy for socioeconomic status. this was assessed as a categorical variable representing low, medium, and high socioeconomic regions. Year of diagnosis was analyzed as a categorical variable (2000-2003, 2004-2006, and 2007-2009 ). finally, we obtained pathologic t stage of the patient's tumor directly from the seeR Patient entitlement and Diagnosis summary file.
teaching status and nCi designation of the hospital were obtained from the hospital file. to obtain surgeonspecific information, we linked unencrypted unique physician identification numbers associated with the surgical procedure with the medicare Physician identification and eligibility Record database. from this database, we obtained year of medical school graduation and surgical specialty. Year of graduation was included in the analysis as a categorical variable (<1970, 1970-1979, 1980-1989, and 1990 and after). surgical specialty was categorized as general surgeon, colorectal surgeon, and other.
univariate associations between type of resection and patient, surgeon, and hospital characteristics were assessed using χ 2 tests for categorical variables and t tests for continuous variables. multivariable logistic regression was used to analyze the individual association of these variables with type of resection while adjusting for the other variables of interest. the final logistic model included categorical patient age, race, sex, Romano-Charlson score, socioeconomic status, year of diagnosis, and tumor t stage; surgeon medical school graduation year and surgical specialty; and hospital nCi status and teaching status. two-tailed tests were used for all of the analyses, and statistical significance was defined at p < 0.05. statistical analysis was conducted using stata 12.0 (stataCorp, College station, tX).
RESULTS
We identified 8966 patients who had either le or RR for tis/t1/t2 rectal cancer from 2000 to 2009. of these patients, 6085 (67.9%) underwent RR, whereas 2881 (32.1%) underwent le. in univariate analysis, the use of le decreased significantly between 2000 and 2009 (table 1). in 2000-2003, the rate of le was 33.6% compared with 29.8% between 2007 and 2009. older patients, women, and those with higher comorbidity indexes were more likely to undergo le. in addition, patients treated by a colorectal surgeon were more likely to have undergone le than those treated by a general surgeon (colorectal, 43.8% vs general, 29.9%; p < 0.001). similarly, younger surgeons were more likely to perform les. although colorectal surgeons used le more frequently than general surgeons, over time, the use of le by colorectal surgeons decreased to a greater degree (5.4% vs 1.8% decrease), although the change was not statistically significant ( fig. 1) .
Patients who were not white or black were less likely to undergo le (white, 32.6% vs other, 28.3%; p = 0.03). increasing t stage was also associated with decreased likelihood of le. overall, the rate of le for t2 tumors was 21.7% compared with 37.1% and 44.4% for t1 and in situ tumors (p < 0.001). over time, the decreased use of le was most pronounced in t1 tumors where the rate decreased from 39.9% to 34.1% (p = 0.02; fig. 2) in the univariate analysis, le was less frequent in nCidesignated hospitals (non-nCi, 32.4% vs nCi, 25.2%; p = 0.009). Conversely, le was slightly more frequent at teaching hospitals (19.5%) than nonteaching hospitals (15.3%). of note, le was far more commonly (81.1%) performed at facilities with an unknown teaching status, likely because this category captures outpatient surgery centers that do not have specific information included in the hospital file. Because les can be done on an outpatient basis, it follows that these facilities would represent a large percentage of the le volume.
Rates of adjuvant therapy did not change significantly over time for any t-stage group. overall, patients who received le for their tumor were significantly more likely to receive adjuvant therapy. After LE, 19.4% of patients with T1 tumors received adjuvant therapy, whereas 5.1% of T1 patients who underwent proctectomy received adjuvant therapy (p < 0.001). similarly, 41.5% of patients who underwent le and only 7.8% of those who underwent proctectomy with T2 tumors received adjuvant therapy (p < 0.001). The rate of adjuvant therapy in patients who underwent le did not change significantly over time in any t stage group.
Patient
Characteristics older age was associated with significantly and continuously increased odds of undergoing le (table 2) . similarly, patients with Charlson scores ≥2 were more likely to undergo le compared with patients with Charlson scores of 0 (oR, 1.40; p < 0.001). men had lower odds of overall, our study demonstrates that, over a 10-year period, after a significant global evaluation of le, there was a significant decrease in its use for early stage rectal cancer. interestingly, the absolute change was not dramatic; from 33. Part of this is driven by a significant 6% decrease in the use of le for patients with t1 tumors. for in situ disease, where le is noncontroversial, rates of le were high and decreased minimally ( fig. 2) . similarly, in patients with t2 tumors, rates were lower and did not change significantly.
these results differ from those of a 2013 study that examined patterns of le for early stage rectal cancer from 1998 to 2010 using the national Cancer Data Base (nCDB). these authors reported an increase in the use of le for both t1 and t2 tumors. 21 there are several possible reasons for this difference. most importantly, the nCDB study included patients of all ages, whereas our study included only patients >65 years old. it is likely that the treatment pattern for younger patients with rectal cancer differs from that of older patients and could be responsible for the opposite trend reported in that study. in addition, in the nCDB study, only univariate analysis was used to explore the relationship between year and type of resection. in our study, we included year of diagnosis in our model, which allowed us to adjust for multiple patient, surgeon, and hospital factors that may have served as confounders in the relationship between year and resection type. after multivariable analysis, later diagnosis year was highly related to lower odds of le. finally, in the nCDB study there may be an overestimate of le, as the authors suggest that "a patient could have undergone a subsequent surgical procedure that was not captured." in our study, we looked for subsequent RR codes for patients initially treated with le to ensure that patients who underwent le and were subsequently treated with an RR were included in the RR group. in our study, ~10% of patients initially identified as having an le were found to have a subsequent RR.
Consistent with all le studies, we found that patients who are older and have a higher comorbidity burden are more likely to undergo le. le carries a lower risk of morbidity and mortality in patients with independent risk factors for surgical complications. We also demonstrated that women are more likely to undergo le compared with men. this pattern has been relatively widely reported and is consistent with reports that women with colorectal cancer undergo less aggressive therapy than men.
10,21,31,32 in our study there was no adjusted difference in the use of le between white and black patients. We did demonstrate that nonwhite/nonblack patients are less likely to undergo le. although others have reported increased rates of le in black patients, most studies have reported no racial disparity. 10, 21, 31, 33 in addition, almost all reports of racial discrepancy in the use of le have been based on univariate analysis only. Given that le carries an increased risk of recurrence and decreased survival for select tumors, understanding and clarifying these demographic discrepancies could be important in optimizing rectal cancer survival across sex and racial divides.
the type of institution also correlated with the odds of receiving an le. Patients treated at teaching and nCi centers were more likely to undergo le. it is possible that at these institutions specialty specific treatment and multidisciplinary consideration may steer therapy. in addition, availability of specialized equipment, such as tem, may extend the ability to offer a transanal approach. finally, patients who are resistant to traditional resection, especially if a permanent stoma is required, may seek out academic centers where less traditional strategies may be offered.
age and specialization of the surgeon significantly affect procedure choice. Patients treated by younger surgeons and those fellowship trained in colorectal surgery were more likely to undergo le. Better exposure to techniques, indications, and limitations of a transanal approach through fellowship training may account for these differences. similarly, the development of tem is an application almost exclusively used by colorectal surgeons. even more pronounced than specialty was the relationship between surgeon age and the use of le. surgeons graduating from medical school after 1990 were almost twice as likely to perform an le for early stage rectal cancer as surgeons graduating before 1970. RR has long been the standard for treating rectal cancer, and it is possible that older surgeons are less prone to deviate from the standard of surgical care or less likely to adopt tem. a strength of this study is the use of a patient cohort of ~9000 patients with early stage rectal cancer. in addition, the seeR cancer database is well recognized for stringent collection standards and is viewed as a reliable database. finally, the combination of the patient information with the hospital and physician information available to us provides a unique data set for the evaluation of patterns of use of le. this combination of data allowed for a robust multivariable analysis that is unique in the literature and presents a very thorough examination of the factors related to the use of le.
the study has limitations inherent to large administrative data sets. although there are extensive measures in place to ensure quality controls, this leaves room for error related to miscoding and omission. in addition, and more importantly, we cannot use claims and registry data to ascertain causality for the demonstrated associations. additional studies with chart review or surgeon interviews would be required to more accurately ascertain why certain factors are associated with the use of le. the limitation of analysis to only those between ages 66 and 99 years is perhaps a larger problem. the treatment of rectal cancer in those <66 years old may look very different from those of an older age. Despite this, the median age of rectal cancer diagnosis is 69 years old, and more than 50% of patients diagnosed with the disease are >65 years old, so these observations are applicable to a majority of the population with rectal cancer.
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CONCLUSION
the use of le for rectal cancer in the medicare population has changed since data from in the 2000s revealed a higher rate of recurrence and raised widespread alarm. the steady use of le for the treatment of t2 tumors lately may reflect confidence in subsequent prospective trial data showing that its use in combination with chemotherapy and radiation can be safe and effective. 35 fewer guidelines exist for the treatment of distal t1 tumors, and the diminished use of le for these tumors recently may reflect the complexity of decision analysis in these cases. up-to-date knowledge of the controversies and debates, fellowship training, and access to better technology for transanal approaches may influence their use in younger, fellowshiptrained surgeons.
